Form 4: Summit Therapeutics Co-CEO Zanganeh Receives Amended Stock Options
SEC Form 4 Filing
Mahkam Zanganeh, Co-CEO of Summit Therapeutics, reports amended stock options converting performance-based options to time-based vesting.
Summary
- Mahkam Zanganeh, Co-Chief Executive Officer of Summit Therapeutics Inc., filed a Form 4 on May 1, 2025, reporting changes in beneficial ownership.
- The report details the amendment of performance-based stock options to time-based stock options effective April 29, 2025.
- Zanganeh holds options to buy 1,040,000 shares at $1.06, 400,000 shares at $1.29, and 9,590,558 shares at $1.68.
- 50% of the shares underlying the amended options vested on April 29, 2025, with the remaining 50% vesting in three equal annual installments starting October 13, 2025.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing detailing changes in executive compensation. It doesn't contain any particularly positive or negative news, hence a neutral sentiment score.
Positives
- The conversion to time-based vesting may provide more predictable compensation for the Co-CEO.
Future Outlook
The remaining 50% of the shares will vest in three equal annual installments starting October 13, 2025.
Industry Context
Stock option grants and amendments are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry, often benchmarked against peer companies of similar size and stage of development.
- Vesting schedules, like the one described, are typical, with a mix of immediate and deferred vesting to align executive interests with long-term company performance.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation strategy.
Stakeholder Impact
- The vesting of stock options could potentially dilute existing shareholders' equity over time.
Key Dates
| Date | Description |
|---|---|
| 04/29/2025 | Effective date of stock option amendment (performance-based to time-based); 50% of shares vested. |
| 05/01/2025 | Date of Form 4 filing. |
| 10/13/2025 | First annual installment vesting date for remaining 50% of shares. |
| 06/28/2032 | Expiration date for options to buy 1,040,000 shares at $1.06. |
| 09/09/2032 | Expiration date for options to buy 400,000 shares at $1.29. |
| 10/13/2033 | Expiration date for options to buy 9,590,558 shares at $1.68. |
Keywords
stock options, Summit Therapeutics, Form 4, beneficial ownership, Zanganeh, Co-CEO, time-based vesting, performance-based
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.